Imatinib attenuates myocardial fibrosis in association with inhibition of the PDGFRα activity

Arquivos Brasileiros de Cardiologia

Volumn 99, Issue 6, 2012, Pages 1082-1091

  Ma, Li Kun ^a   Li, Qian ^a   He, Li Feng ^a   Hua, Jin Sheng ^a   Zhou, Jun Ling ^a   Yu, Hua ^a   Feng, Ke Fu ^a   Chen, Hong Wu ^a   Hu, Hao ^a   Wang, Lin ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Desoxycorticosterone; Endomyocardial fibrosis; Eph family; Platelet derived growth factor alpha; Receptor; Receptors

Indexed keywords

DEOXYCORTICOSTERONE; FIBRONECTIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR C; PROCOLLAGEN; TENASCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; HEART MUSCLE FIBROSIS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MONOCYTE; MYOCARDITIS; NONHUMAN; PATHOLOGY; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING;

ANIMALS; BENZAMIDES; BLOOD PRESSURE; BLOTTING, WESTERN; DESOXYCORTICOSTERONE; DISEASE MODELS, ANIMAL; ENDOMYOCARDIAL FIBROSIS; FIBRONECTINS; FIBROSIS; HYPERTENSION; MALE; NEPHRECTOMY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TENASCIN; TREATMENT OUTCOME;

EID: 84872913443     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2012005000109     Document Type: Article

References (40)

1. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol. 2002;283(3):H1253-62.
2. Isoda K, Kamezawa Y, Tada N, Sato M, Ohsuzu F. Myocardial hyperthrophy in transgenic mice overexpressing human interleukin 1α. J Card Fail. 2001;7(4):355-64.
3. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, et al. Cardiac failure in transgenic mice with myocardial expression of tumornecrosis factor-alpha. Circulation. 1998;97(14):1375-81.
4. Pontén A, Li X, Thorén P, Aase K, Sjöblom T, Ostman A, et al. Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy. Am J Pathol. 2003;163(2):673-82.
5. Wu E, Palmer N, Tian Z, Moseman AP, Galdzicki M, Wang X, et al. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One. 2008;3(11):e3794.
6. Habibi J, DeMarco VG, Ma L, Pulakat L, Rainey WE, Whaley-Connell AT, et al. Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol. 2011;300(4):H1484-1491.
7. Dooley R, Harvey BJ, Thomas W. The regulation of cell growth and survival by aldosterone. Front Biosci. 2011;16:440-57.
8. Ishimaru K, Ueno H, Kagitani S, Takabayashi D, Takata M, Inoue H. Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/ macrophage infiltration in the Heart of DOCA/Salt hypertensive rats. J Cardiovasc Pharmacol. 2007;50(2):187-94.
9. Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem. 2006;13(16):1877-93.
10. Eddy A. Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis. 2001;7(Suppl 2):S25-9.
11. Dorrance AM. Are macrophages the foot soldiers in the war waged by aldosterone against the heart? Hypertension. 2009;54(3):451-3.
12. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against DOC/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009; 54(3):537-43.
13. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schütz G, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010;120(9):3350-64.
14. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47(4):656-64.
15. Ostendorf T, Kunter U, Grone HJ, Bahlmann F, Kawachi H, Shimizu F, et al. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol. 2001;12(5):909-18.
16. Eitner F, Ostendorf T, Kretzler M, Cohen CD, Eriksson U, Grone HJ, et al. ERCB-Consortium. PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. J Am Soc Nephrol. 2003;14(5):1145-53.
17. Leeb SN, Vogl D, Falk W, Scholmerich J, Rogler G, Gelbmann CM. Regulation of migration of human colonic myofibroblasts. Growth Factors. 2002;20(2):81-91.
18. Bonner JC, Lindroos PM, Rice AB, Moomaw CR, Morgan DL. Induction of PDGF receptor-alpha in rat myofibroblasts during pulmonary fibrogenesis in vivo. Am J Physiol. 1998;274 (1 Pt 1):L72-80.
19. Lindroos PM, Wang YZ, Rice AB, Bonner JC. Regulation of PDGFR-alpha in rat pulmonary myofibroblasts by staurosporine. Am J Physiol Lung Cell Mol Physiol. 2001;280(2):L354-62.
20. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis. 2001;21(3):397-416.
21. Bonner JC, Goodell AL, Coin PG, Brody AR. Chrysotile asbestos upregulates gene expression and production of alpha-receptors for platelet-derived growth factor (PDGF-AA) on rat lung fibroblasts. J Clin Invest. 1993;92(1):425-30.
22. Leipner C, Grün K, Müller A, Buchdunger E, Borsi L, Kosmehl H, et al. Imatinib mesylate attenuates fibrosis in COXsackievirusb3-induced chronic myocarditis. Cardiovasc Res. 2008;79(1):118-26.
23. Leask A. Potential therapeutic targets for cardiac fibrosis: TGF beta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res. 2010;106(11):1675-80.
24. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 2004;15(4):237-54.
25. Liao CH, Akazawa H, Tamagawa M, Ito K, Yasuda N, Kudo Y, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest. 2010;120(1):242-53.
26. Yang D, Qiu D. Linkage between elevated PDGF-C expression and myocardial fibrogenesis in coxsackievirus B3-induced chronic myocarditis. Eur Heart J. 2005;26(7):642-3.
27. Grün K, Markova B, Böhmer FD, Berndt A, Kosmehl H, Leipner C. Elevated expression of PDGF-C in coxsackievirus B3-induced chronic myocarditis. Eur Heart J. 2005;26(7):728-39.
28. Pontén A, Folestad EB, Pietras K, Eriksson U. Platelet-derived growth factor D induces cardiac fibrosis and proliferation of vascular smooth muscle cells in heart-specific transgenic mice. Circ Res. 2005;97(10):1036-45.
29. Simm A, Nestler M, Hoppe V. Mitogenic effect of PDGF-AA on cardiac fibroblasts. Basic Res Cardiol. 1998;93(Suppl 3):40-3.
30. Simm A, Nestler M, Hoppe V. PDGF-AA, a potent mitogen for cardiac fibroblasts from adult rats. J Mol Cell Cardiol. 1997;29(1):357-68.
31. Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol. 2000;2(5):302-9.
32. Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys. 2002;398(2):284-90.
33. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276-312.
34. Zymek P, Bujak M, Chatila K, Cieslak A, Thakker G, Entman ML, Frangogiannis NG. The role of platelet-derived growth factor signaling in healing myocardial infarcts. J Am Coll Cardiol. 2006;48(11):2315-23.
35. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004;15(4):255-73.
36. Chaudhary NI, Roth GJ, Hilberg F, Müller-Quernheim J, Prasse A, Zissel G, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29(5):976-85.
37. Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Thannickal VJ. Effects of the Protein Kinase Inhibitor, Imatinib mesylate, on epithelial/mesenchymal phenotypes:Implications for treatment of fibrotic diseases. J Pharmacol Exp Ther. 2007;321(1):35-44.
38. Savikko J, Taskinen E, Von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation. 2003;75(8):1147-53.
39. Nishioka T, Suzuki M, Onishi K, Takakura N, Inada H, Yoshida T, et al. Eplerenone Attenuates Myocardial Fibrosis in the Angiotensin II-Induced Hypertensive Mouse: Involvement of Tenascin-C Induced by Aldosterone-Mediated Inflammation. J Cardiovasc Pharmacol. 2007; 49(5): 261-8.
40. Eismann U, Sommer M, Kosmehl H, Appenroth D, Fleck C, Stein G. Fibronectin splice variants-prognostic markers for the stage of renal interstitial fibrosis in the rat. Nephron. 2002;92(2):379-88.